The Biosimilar industry in Korea is a rapidly growing sector that has shown significant progress in recent years. Biosimilars are biological products that are highly similar to already approved biologic drugs and are designed to provide cost-effective alternatives for patients.

In this session, we will explore the reasons behind Korea’s success in the biosimilar industry, the challenges faced by Korean companies, and the impact of Korea’s biosimilar industry on the global healthcare market. We will also discuss the regulatory framework for biosimilars in Korea and compare it to other countries.